Penicillin-Resistant Group B Strep Identified in Italy for First Time

Italy identified its first penicillin-resistant strain of Streptococcus agalactiae, commonly known as Group B Streptococcus or GBS, in an adult patient in February 2026, Il Sole 24 ORE reported.

The finding marks a critical shift for the pathogen, which serves as the primary antibiotic treatment for both invasive infections and intra-partum prophylaxis during childbirth.

The Istituto Superiore di Sanità released the finding ahead of the European Antibiotic Awareness Day, noting that overall antimicrobial resistance rates in Italy remain high despite minor improvements. The World Health Organization classified penicillin-resistant GBS as a medium-priority pathogen in 2024, warning that the loss of beta-lactam efficacy threatens global public health and neonatal safety.

Molecular Mutations Drive Resistance in the Piacenza Isolate

The Ausl di Piacenza isolated the bacterium from an adult patient’s blood culture in February 2026 and forwarded the sample to the Istituto Superiore di Sanità for resistance confirmation and molecular characterization. Laboratory analyses and genomic sequencing confirmed that the strain, identified as serotype Ia and Sequence Type 23, exhibited a minimum inhibitory concentration (MIC) value of 0.25 mg/L.

This resistance stems from known point mutations identified de novo within the genes encoding penicillin-binding proteins pbp2a and pbp2x. Furthermore, laboratory profiling revealed that the bacterial isolate displayed resistance to several alternative drug classes, including levofloxacin, erythromycin, and tetracycline.

“This first national isolation, published in Eurosurveillance, imposes maintaining high guard on the territory to protect the effectiveness of prevention and treatment protocols.”

The Istituto Superiore di Sanità emphasized that public health authorities must monitor local infection vectors closely to preserve clinical intervention strategies. The emergence of multi-drug resistance in a pathogen traditionally susceptible to first-line penicillin therapies complicates clinical management for vulnerable populations, particularly pregnant individuals and newborns.

In Plain English: The Clinical Takeaway

  • Group B Streptococcus (GBS): A common bacterium that can cause severe infections, particularly in newborns and vulnerable adults, typically treated easily with penicillin.
  • Penicillin Resistance: The ability of bacteria to survive exposure to standard beta-lactam antibiotics, requiring alternative pharmacological approaches.
  • Minimum Inhibitory Concentration (MIC): A laboratory measurement indicating the lowest concentration of an antimicrobial drug needed to stop bacterial growth.

Surveillance Systems and Regional Public Health Measures

Alongside the identification of the resistant strain, national health data indicate that consumption rates for hydroalcoholic hand hygiene solutions in hospitals have risen slightly across Italy. However, these usage metrics remain below the benchmarks recommended by the World Health Organization for effective infection control.

Addressing antimicrobial resistance requires coordinated systemic responses across research, clinical surveillance, and healthcare policy development.

“Contrastare la resistenza agli antibiotici per preservare la loro efficacia nel curare le infezioni e le loro conseguenze sulla salute e sui sistemi sanitari. Questo il fondamentale messaggio dell’evento che vogliamo condividere con tutti gli attori coinvolti. Contrastare le resistenze necessita di molte azioni integrate che includono sorveglianza, ricerca, politiche sanitarie, sviluppo di nuove strategie diagnostiche preventive e terapeutiche. Si tratta di un problema complesso che necessita di interventi collaborativi di lunga durata che il nostro sistema è chiamato ad affrontare.”

The surveillance framework tracks the spread of the Sequence Type 23 strain to prevent secondary transmission within hospitals.

Parameter Details
Pathogen Streptococcus agalactiae (Group B Streptococcus)
Resistance Profile Penicillin (MIC 0.25 mg/L), levofloxacin, erythromycin, tetracycline
Genomic Characterization Serotype Ia, Sequence Type 23, pbp2a and pbp2x mutations
Reporting Agency Istituto Superiore di Sanità (ISS)

Guidelines for Prenatal Screening and Antibiotic Use

Pregnant individuals must adhere strictly to established prenatal screening protocols for Group B Streptococcus to ensure timely intra-partum prophylaxis. Healthcare providers must evaluate regional resistance patterns before administering empiric antibiotic therapy, avoiding broad-spectrum agents when targeted diagnostics can identify susceptible alternatives. Self-medication with leftover antibiotics is strictly contraindicated, as improper dosing accelerates antimicrobial resistance.

References

  • Istituto Superiore di Sanità (ISS) Public Health Reports.
  • Eurosurveillance Epidemiological Updates on Antimicrobial Resistance.
  • World Health Organization Global Priority Pathogens List.
Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Xiaomi 18 Pro Series Launched Globally with Leica Camera

Türkiye U19 Beats Liechtenstein 11-2, Karadeniz Scores 5